$CNO

9,336-share cashout at CNO Financial (NYSE: CNO) follows $515,366 stock sale

CNO Financial Group (CNO) disclosed that officer Karen DeToro plans to sell 9,336 shares of CNO common stock, valued at $511,002.96 as of September 1, 2026. The planned sales include 1,836 restricted shares and 7,500 shares from a stock option exercise. DeToro also reported a prior sale of 9,374 shares on August 31, 2026 for $515,366.21.

Original reporting
Published Sep 1, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 5:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CNO
Neutral
high confidence
Mentioned
$CNO
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CNONeutralLow
01

Why it matters

The disclosed sale adds a modest amount of shares to the market, unlikely to affect price materially, but provides transparency for investors.

02

Market read

Routine insider sale with limited trading relevance; primarily of interest to existing shareholders and compliance monitors.

03

What to watch

Potential upcoming earnings or strategic announcements that may amplify the impact of the insider sale.

Relevance 4/10Novelty 4/10Timing: September 1, 2026 (filing date)

Background

Form 144 filing by a CNO officer discloses planned insider sales, a standard regulatory requirement for restricted shares.

Company-level read

Ticker impact

$CNONeutralHigh confidence
Context

Officer Karen DeToro filed a Form 144 to sell 9,336 CNO shares worth $511,003, after a prior sale of 9,374 shares for $515,366.

Expected impact

Minimal short‑term impact; price likely to stay within current range.

Evidence & confidence

The transaction size (~$0.5 M) is small relative to CNO's market cap and typical daily volume, so any price effect will be limited.

Market effects

None; the sale is company‑specific and does not affect the broader financial services sector.

No regional effect; the filing is a routine insider transaction.

Low; limited to CNO shareholders.

Counterpoint

If the insider is reducing exposure, it could signal concerns about near‑term performance, warranting a closer look.

Key entities

  • CNO Financial Group, Inc.

    US‑listed insurer and financial services firm (ticker CNO).

  • Karen DeToro

    Officer of CNO filing the Form 144 sale.

Related articles

$CNOMed

California Nanotechnologies Posts 28% Revenue Growth in Q1 FY2027 as Nuclear Pivot Takes Hold

California Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.

$CNOHighAI 9/10

CNO Financial (CNO) Q2 2026 Earnings Call Transcript

CNO Financial Group (NYSE:CNO) reported Q2 2026 operating EPS of $1.26, up 45% year over year, and net operating income of $119.5 million. Total new annualized premiums rose 7% to a record. Full-year EPS guidance was raised to $4.60 to $4.80. The company also repurchased $60 million of shares.

$CNOMed

CNO Financial posts insurance income gain on 16-quarter sales streak

CNO Financial Group reported Q2 2026 sales growth for a 16th consecutive quarter. Insurance policy income rose to $680.7 million from $651.3 million a year earlier, and net income increased to $125.9 million, or $1.33 per diluted share, from $91.8 million, or $0.91. CNO raised full-year 2026 operating EPS guidance by 8% at the midpoint and estimated RBC at 377% as of June 30.

$CNOMed

CNO Financial Group’s (NYSE:CNO) Q2 CY2026 Sales Beat Estimates

Insurance services company CNO Financial Group (NYSE: CNO) announced better-than-expected revenue in Q2 CY2026, with sales up 34.6% year on year to $1.29 billion. Its GAAP profit of $1.33 per share was 36.4% above analysts’ consensus estimates. Is now the time to buy CNO Financial Group? Find out by accessing our full research report, it’s free.

$CNOLow

CNO Financial Group, Inc. (CNO): Results of Operations and Financial Condition

CNO Financial Group, Inc. (CNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. News For Immediate Release CNO Financial Group Reports Second Quarter 2026 Results Carmel, Ind., July 30, 2026 - CNO Financial Group, Inc. (NYSE: CNO) today reported its second quarter 2026 financial results: • Strong execution and momentum continues; Raising 2026 operating earni